Skip to main content

Avapag 20 mg ( Avatrombopag)

Avapag 20 mg is identified on this website as a medicine containing avatrombopag, an oral thrombopoietin receptor agonist. This type of medicine stimulates platelet production in the bone marrow. The stated product strength is 20 mg.

The active ingredient stated for Avapag is avatrombopag. Avatrombopag acts on thrombopoietin receptors involved in the development and production of platelets.

Avatrombopag belongs to a class of medicines called thrombopoietin receptor agonists (TPO-RAs). These medicines stimulate the body's platelet-producing cells and can increase platelet counts in selected patients.

TPO-RA stands for thrombopoietin receptor agonist. Thrombopoietin is a natural protein involved in platelet production. A TPO-RA activates the relevant receptor to stimulate the development of platelet-producing cells.

Avatrombopag is a prescription medicine in the established treatment settings discussed on this website. Patients should use Avapag only after confirming its product-specific status and receiving appropriate instructions from a qualified healthcare professional.

The product is identified as Avapag 20 mg. The stated strength refers to the amount of avatrombopag per unit of the described product, subject to confirmation from its packaging and official documentation.

Medical Uses and Treatment

Established adult uses of avatrombopag include thrombocytopenia associated with chronic liver disease in patients scheduled to undergo a medical procedure, and chronic immune thrombocytopenia in adults who have had an insufficient response to previous treatment.

Thrombocytopenia is a condition in which the blood contains fewer platelets than expected. Platelets help the blood form clots and control bleeding. A low platelet count may increase the risk of bruising or bleeding, depending on its severity and underlying cause.

Chronic immune thrombocytopenia is an autoimmune condition in which the immune system mistakenly targets and destroys platelets. It can cause low platelet counts, bruising, skin spots and bleeding symptoms.

Some people with chronic liver disease develop thrombocytopenia. Avatrombopag may be prescribed to increase platelet counts before a scheduled medical procedure when the patient meets the relevant treatment criteria.

No. Avatrombopag stimulates platelet production but does not cure the underlying autoimmune process responsible for ITP. It is used to help manage platelet counts in appropriately selected patients.

Yes. Avatrombopag stimulates the thrombopoietin receptor and promotes platelet production. The extent and timing of the response vary between individuals, so blood tests are needed to monitor treatment.

No. Its established uses are specific. A low platelet count can have many causes, and avatrombopag is not appropriate for every form of thrombocytopenia. A healthcare professional must identify the underlying condition before treatment.

Dosage and Administration Questions

The reference adult tablet regimen for avatrombopag starts at 20 mg once daily with food. The dose may be adjusted according to platelet-count response. This is reference-product information, not a confirmed Avapag-specific regimen.

For the reference tablet product, the five-day regimen depends on the platelet count before a scheduled procedure. The reference prescribing information describes 60 mg daily when the count is below 40 × 10⁹/L and 40 mg daily when it is 40 to below 50 × 10⁹/L. Only a qualified clinician should determine whether this treatment is appropriate.

The reference avatrombopag tablet prescribing information instructs patients to take the medicine with food. Always check the instructions supplied with the specific product being used.

The appropriate administration time depends on the prescribed schedule. Patients should follow the instructions provided by their healthcare professional and take the medicine consistently as directed.

Do not split, crush or alter an Avapag tablet unless its official product instructions or a healthcare professional specifically confirm that this is appropriate. The product's formulation and administration instructions should first be verified.

Follow the missed-dose instructions for the specific product and indication. Do not take an extra or double dose to compensate. Contact your pharmacist or prescribing clinician if you are unsure.

Do not discontinue treatment without medical advice. Your platelet count may change after treatment stops, so your clinician may recommend follow-up blood tests.

Side Effects and Safety Questions

Reported adverse reactions vary by indication. For the reference product, commonly reported reactions include headache, fatigue, nausea, abdominal pain, fever, bruising, nosebleeds, joint pain and peripheral edema. Not everyone experiences these effects.

Yes. Headache is among the reported adverse reactions associated with reference-product avatrombopag treatment. Contact a healthcare professional if headaches are severe, persistent or unusual.

Bruising and bleeding-related symptoms, including nosebleeds and gum bleeding, have been reported in patients treated for chronic ITP. Report unusual or persistent bleeding to your healthcare professional.

Yes. Thrombotic and thromboembolic complications have been reported with thrombopoietin receptor agonists, including reference-product avatrombopag. Patients should be monitored for symptoms and relevant risk factors.

Possible warning signs include sudden chest pain, difficulty breathing, one-sided leg swelling or pain, sudden weakness, difficulty speaking or sudden changes in vision. Seek urgent medical assessment if these symptoms occur.

Avatrombopag can increase platelet counts. This is why regular blood testing and clinician-directed dose adjustments are important. Treatment should aim for the appropriate platelet response rather than a normal platelet count.

People with a history of blood clots, known clotting disorders, chronic liver disease or other significant medical conditions should discuss their risks with a healthcare professional before treatment.

Some medicines may affect avatrombopag exposure. Tell your doctor about all prescription medicines, nonprescription medicines, vitamins and supplements you use. Your clinician or pharmacist can check for possible interactions.

Special Populations and Lifestyle Questions

Pregnancy should be discussed with a healthcare professional before treatment. The reference product prescribing information includes a warning about potential fetal harm. Do not start or continue treatment during pregnancy without specialist medical guidance.

The reference product prescribing information advises against breastfeeding during treatment. Discuss the benefits and risks with your healthcare professional before making decisions about treatment or breastfeeding.

The U.S. reference-product information includes specific treatment provisions for children aged one year and older with persistent or chronic ITP who have not responded sufficiently to previous treatment. Different dosage forms are specified for different age groups. This does not establish pediatric authorization or suitability for Avapag itself.

Age alone does not determine whether treatment is appropriate. A healthcare professional should consider overall health, other medical conditions, current medicines and platelet-count response.

There is no universal alcohol instruction that applies to every patient. People with chronic liver disease should discuss alcohol consumption with their treating clinician, who can consider their liver condition and complete treatment plan.

Ask your healthcare professional whether driving is appropriate for you. Avoid driving if you experience symptoms such as dizziness, significant fatigue or any other effect that could impair alertness.

Monitoring, Storage and Product Questions

Yes. Platelet-count monitoring is essential. The schedule depends on the indication and treatment response. For the reference adult ITP regimen, platelet counts are monitored weekly until stable and monthly thereafter, with weekly monitoring for at least four weeks after discontinuation.

The reference tablet product can begin increasing platelet counts within several days. The timing and extent of response vary among patients, and blood tests are needed to assess the effect.

Follow the storage instructions printed on the specific product packaging and patient information leaflet. Keep medicines in their original packaging when appropriate, away from children, and do not use them after their expiry date.

Check the product name, stated active ingredient, strength, packaging integrity, batch number, expiry date and manufacturer details. Confirm the product's regulatory status through the appropriate national regulatory authority or qualified pharmaceutical professional.

No. Avapag and Doptelet are different product names. Doptelet is a reference avatrombopag brand with published prescribing information. Its manufacturer, authorization and dosing details should not automatically be attributed to Avapag.

Start with the product's official packaging, patient information leaflet and prescribing documentation. For treatment decisions, consult a qualified healthcare professional. Product-specific manufacturer and regulatory details should be checked through appropriate official records.